|
|
Pharmacology & human Phase 1 safety & dose escalation studies using anti-GP88 in aggressive breast cancer
|
1R44CA224718-01A1
|
$159,365
|
$159,365
|
SERRERO, GINETTE
|
A AND G PHARMACEUTICAL, INC.
|
|
|
A Circulating Biomarker for use in Monitoring Metastatic Breast Cancer
|
2R44CA210817-02
|
$1,101,350
|
$1,101,350
|
SERRERO, GINETTE
|
A AND G PHARMACEUTICAL, INC.
|
|
|
Antibody targeting of ADAM8 for treatment of triple-negative breast cancer
|
2R44CA200161-02A1
|
$1,000,000
|
$1,000,000
|
SONENSHEIN, GAIL
|
ADECTO PHARMACEUTICALS, INC.
|
|
|
Antibody targeting of ADAM8 for treatment of triple-negative breast cancer
|
3R41CA200161-01A1S3
|
$3,000
|
$3,000
|
SONENSHEIN, GAIL
|
ADECTO PHARMACEUTICALS, INC.
|
|
|
The Hemopurifier Device for Targeted Removal of Breast Cancer Exosomes from the Blood Circulation
|
1R43CA232977-01
|
$298,444
|
$298,444
|
MARLEAU, ANNETTE
|
AETHLON MEDICAL, INC.
|
|
|
A Novel Immunotherapy Targeting Cancer Stem Cells for the Treatment of Triple-Negative Breast Cancer
|
1R44CA224835-01A1
|
$298,864
|
$298,864
|
PERICLE, FEDERICA
|
AGILVAX, INC.
|
|
|
Integrin Regulation of Cancer Progression Through Alternative mRNA Splicing and Nonsense-Medidated Decay (NMD)
|
5R01CA129637-08
|
$375,250
|
$375,250
|
DIPERSIO, C MICHAEL
|
ALBANY MEDICAL COLLEGE
|
|
|
MOTILITY AND INVASION
|
5P01CA100324-16
|
$2,028,990
|
$2,028,990
|
CONDEELIS, JOHN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Signal transduction regulating tumor cell dissemination
|
5R01CA150344-30
|
$396,625
|
$396,625
|
CONDEELIS, JOHN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
(7) Novel imaging devices for measurement and control of tumor microenvironments
|
5R01CA216248-02
|
$607,904
|
$607,904
|
CONDEELIS, JOHN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Core Support for Cancer Center
|
3P30CA013330-45S1
|
$3,646,138
|
$1,166,764
|
GOLDMAN, ISRAEL
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Inhibition of Senescence to Increase Cancer Cell Death: A New Paradigm
|
5R01CA077263-19
|
$417,500
|
$137,775
|
MCDAID, HAYLEY
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Molecular markers of risk of subsequent invasive breast cancer in women wth ductal carcinoma in situ
|
5R01CA218429-02
|
$1,347,851
|
$1,347,851
|
ROHAN, THOMAS
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
The B7x pathway in the tumor microenvironment
|
5R01CA175495-06
|
$346,525
|
$69,305
|
ZANG, XINGXING
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
A NOVEL SMALL MOLECULE CX3CR1 ANTAGONIST HALTS METASTASIS
|
5R44CA183362-03
|
$789,107
|
$394,554
|
SALVINO, JOSEPH
|
ALLIANCE DISCOVERY, INC.
|
|
|
Highly Multiplexed Nanoscale Mass Spectrometric Imaging of Cancer Tissues
|
1R43CA236097-01
|
$300,000
|
$300,000
|
LIM, MARK
|
AMBERGEN, INC
|
|
|
Molecular, cancer-specific, intraoperative imaging of breast surgical margin assessment
|
1R41CA221595-01A1
|
$300,000
|
$300,000
|
SHIH, WEI-HENG
|
AQD LIFE SCIENCES, LLC
|
|
|
Immunosignatures to Distinguish Breast Cancer Subtypes and Cancer Recurrence
|
5R21CA220150-02
|
$123,600
|
$123,600
|
JOHNSTON, STEPHEN
|
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
|
|
|
Novel approaches to study immune responses to post translational modifications for cancer detection
|
5U01CA214201-03
|
$607,578
|
$303,789
|
LABAER, JOSHUA
|
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
|
|
|
Couple Communication in Cancer: A Multi-Method Examination
|
3R01CA201179-03S1
|
$227,376
|
$113,688
|
LANGER, SHELBY
|
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
|
|
|
Couple Communication in Cancer: A Multi-Method Examination
|
5R01CA201179-03
|
$655,095
|
$327,548
|
LANGER, SHELBY
|
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
|
|
|
Effects of Meditative Movement (Qigong/Tai Chi Easy) on Fatigued Breast Cancer Survivors
|
3R01CA182901-04S1
|
$39,254
|
$39,254
|
LARKEY, LINDA
|
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
|
|
|
Effects of Meditative Movement (Qigong/Tai Chi Easy) on Fatigued Breast Cancer Survivors
|
5R01CA182901-04
|
$612,939
|
$612,939
|
LARKEY, LINDA
|
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
|
|
|
Proteasome inhibitors for the treatment of solid tumors
|
5R01CA213223-02
|
$356,014
|
$356,014
|
KISSELEV, ALEXEI
|
AUBURN UNIVERSITY AT AUBURN
|
|
|
DACH1/Eya Cell fate determination factor and mammary tumorigenesis
|
5R01CA132115-09
|
$428,056
|
$428,056
|
PESTELL, RICHARD
|
BARUCH S. BLUMBERG INSTITUTE
|
|
|
PNNL Proteome Characterization Center
|
5U24CA210955-03
|
$1,063,923
|
$351,095
|
LIU, TAO
|
BATTELLE PACIFIC NORTHWEST LABORATORIES
|
|
|
A novel N-Ras pathway driving DCIS to basal-like breast cancer
|
1R21CA226567-01
|
$212,055
|
$212,055
|
CHANG, ERIC
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Crosstalk between the ER Stress Response and Mitochondrial Fatty Acid Oxidation in MYC-driven Breast Cancer
|
1R37CA228304-01
|
$362,569
|
$362,569
|
CHEN, XI
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Investigating the mechanisms of CD44s splice isoform in breast cancer metastasis
|
5R01CA182467-06
|
$328,888
|
$328,888
|
CHENG, CHONGHUI
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
MICROSCALED PROTEOGENOMICS FOR CANCER CLINICAL TRIALS
|
5U01CA214125-02
|
$1,413,657
|
$1,413,657
|
ELLIS, MATTHEW
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Translational Breast Cancer Research Training Program
|
1T32CA203690-01A1
|
$194,523
|
$194,523
|
FUQUA, SUZANNE
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Integration of Predictive Biomarkers of Hormone Resistance in Breast Cancer
|
5R01CA072038-20
|
$320,963
|
$320,963
|
FUQUA, SUZANNE
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
MECHANISMS OF AR-ER COLLABORATION IN HORMONE RESISTANCE AND METASTASIS OF BREAST CANCER
|
5R01CA207270-02
|
$362,569
|
$362,569
|
FUQUA, SUZANNE
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Mitochondrial DNA copy number and fat metabolism in triple negative breast cancer
|
5R03CA212816-02
|
$79,250
|
$79,250
|
KAIPPARETTU, BENNY
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
A Novel LGR4 Oncogenic Signaling in Breast Cancer Progression and Metastasis
|
5R01CA204926-02
|
$362,569
|
$362,569
|
LI, YI
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Ruxolitinib for Preventing Breast Cancer in Women on Neuroleptics
|
5R01CA205594-02
|
$362,569
|
$362,569
|
LI, YI
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Novel therapeutics for targeting checkpoint dysfunction in cancer
|
5R01CA203824-02
|
$362,569
|
$271,927
|
LIN, WEEI-CHIN
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
2/2: UHCOP-DLDCCC alliance: Cancer drug discovery/development and education
|
1P20CA221729-01A1
|
$258,006
|
$41,281
|
MATZUK, MARTIN
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Minority PDX Development and Trial Center: Baylor College of Medicine and MD Anderson Cancer Center Collaboration on Mechanistic Studies to Dissect and Combat Health Disparities in Cancer
|
1U54CA233223-01
|
$6,353,982
|
$2,541,593
|
MITSIADES, NICHOLAS
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Translational control of EMT by the CELF1 RNA Binding Protein
|
5R01CA190467-04
|
$362,569
|
$362,569
|
NEILSON, JOEL
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-12S1
|
$118,875
|
$38,040
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-12S2
|
$249,997
|
$79,999
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-12S3
|
$125,004
|
$40,001
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Baylor College of Medicine Cancer Center
|
5P30CA125123-12
|
$3,203,119
|
$1,024,998
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Translational Research in Breast Cancer (SPORE)
|
5P50CA186784-05
|
$2,251,410
|
$2,251,410
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Wnt pathway dynamics in breast cancer metastasis
|
5K22CA207463-02
|
$188,042
|
$188,042
|
ROARTY, KEVIN
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Hormonal Regulation of Breast Cancer
|
2R01CA016303-42A1
|
$480,181
|
$480,181
|
ROSEN, JEFFREY
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Osteogenic Niche Biology in Progression and Endocrine Resistance of Bone Metastases
|
1R01CA221946-01
|
$488,881
|
$244,441
|
ROWLEY, DAVID
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Delineating racially distinct metabolic pathways in triple negative breast cancer
|
5U01CA179674-05
|
$334,143
|
$334,143
|
SREEKUMAR, ARUN
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Drugging the Undruggable Coactivators using Small Molecule Inhibitors
|
5R01CA207701-02
|
$426,451
|
$426,451
|
WANG, JIN
|
BAYLOR COLLEGE OF MEDICINE
|
|
Total relevant funding to Breast for this search: $574,902,164
|
